Thursday, July 30, 2020

Xenobots: The first ever ‘living’ robots

This article is by

Share this article

Article Contributor(s)

Charvi Trivedi

Article Title

Xenobots: The first ever ‘living’ robots

Publisher

Global Views 360

Publication Date

July 30, 2020

URL

A xenobot in simulation and reality

A xenobot in simulation and reality | Source: Sam Kriegman via Computer-Designed Organisms

Creating robots using artificial intelligence has become quite normal in this century. But a robot built with an amalgamation of artificial intelligence and biology is quite enthralling. Researchers from University of Vermont and Tufts University collaborated to conceive a living robot called ‘Xenobot’.

This astounding, millimeter-wide chunk of technology is considered to be ‘living’ as it is created by stem cells from the embryo of Xenopus laevis, an African frog species. These stem cells were selected in such a way that they grew out to be heart and skin cells.

Prior to this, computer scientists at the University of Vermont ran an evolutionary algorithm, which imitates natural selection, on their supercomputer, which yielded the most suitable structures of the robot. After selecting the best designs, biologists at the Tufts University moulded the skin and heart cells into the forms which closely resembled the outputs of the algorithm, through microsurgery.

The resulting biological bodies looked like tiny aliens. "They're neither a traditional robot nor a known species of animal. It's a new class of artifact: a living, programmable organism" said Joshua Bongard, a computer scientist and robotics expert at the University of Vermont, who was involved in the research. Detailed results are published in the Proceedings of the National Academy of Sciences (PNAS) research paper on January 13, 2020.

Newly created xenobots were found to swim in any liquid medium for at least 10 days (or more if put in a nutrient-rich environment) without being fed with any nourishment, since the cells have a reserve of embryonic energy.

Another incredible facet of this technology is that it can revamp any of its parts efficiently upon damage. While technological pieces made out of plastic and metal might cause a lot of pollution after they are disposed of, xenobots are completely biodegradable, causing no harm to the environment. "These xenobots are fully biodegradable, when they're done with their job after seven days, they're just dead skin cells" said Bongard.

One might wonder how these miniscule cell blotches are helpful to us. Well, Xenobots may be very small in size but they can achieve feats which almost no huge, metal-made robot can.

These living robots will be useful in certain fields like medicine wherein they could be utilized to clear plague from our arteries. They can also be modelled with pouches which enables them to carry certain substances. This property can be used for delivering drugs in specific parts of our bodies. Xenobots can also be a boon in the field of cancer biology as they can help reprogramming tumors into normal cells.

Additionally, these tiny biological bodies can be oceans’ best friends. With contaminants like radioactive chemicals, plastics and microplastics creating havoc in the marine world, an immediate need to clean up our water bodies arises. Many xenobots were observed to be moving in circles (an attribute of the beating heart cells), which resembled a ‘clean-up’ motion. Hence, these tiny robots can be a perfect tool to eradicate microplastics from the oceans as well as eliminating nuclear wastes.

Although this technology may be promising, certain ethical questions arise with every technological development, especially those involving biological manipulations. If programmed in a certain way, xenobots can also take over natural biological functions (maybe nerve cells to hamper brain function) and this can be used for nasty purposes.

Michael Levin who directs the Center for Regenerative and Developmental Biology at Tufts said, “That fear is not unreasonable. When we start to mess around with complex systems that we don't understand, we're going to get unintended consequences”. Levin and Bongard are extensively working towards understanding how complex systems work. "There's all of this innate creativity in life. We want to understand that more deeply—and how we can direct and push it toward new forms" said UVM's Josh Bongard.

Like any new disruptive technological innovation, the Xenobots also have the potential to prove boon or bane for the humankind. Let's hope it turns out more boon than bane.

Support us to bring the world closer

To keep our content accessible we don't charge anything from our readers and rely on donations to continue working. Your support is critical in keeping Global Views 360 independent and helps us to present a well-rounded world view on different international issues for you. Every contribution, however big or small, is valuable for us to keep on delivering in future as well.

Support Us

Share this article

Read More

February 4, 2021 5:14 PM

Asian countries & the race for COVID-19 Vaccine

Our relationship with the new strain of coronavirus is almost 8 months strong now. Countries like the US, Russia, UK, China, India, and many more have already set their brainy scientists in the task of developing a vaccine, turning it into a race which desperately needs a winner, since no one wants this deadly relationship to endure. Several attempts have proved to be successful, especially in countries like Russia, USA, India, and China.

China was the first to start scouring for a vaccine the day WHO declared that the new strain of SARS-CoV, originating in Wuhan-China, has resulted in a pandemic. It is a fierce competitor, especially to the US, as almost 8 of the 24 promising vaccines approved for clinical trials are from China. It used the technology of ‘inactivated vaccine’ which basically means killing the actual virus and using that to create a vaccine. This method is quite useful in treating measles and influenza, thus, increasing the chances of success in the case of COVID-19 as well.

“It’s a tried and true strategy”, Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia, said  about the inactivated vaccine. One potential vaccine from China-based Sinopharm is already in the phase 3 of trials whereas Sinovac will enter the third phase this month. Moreover, China has permitted Sinovac and Sinopharm to dilute phase 1 and 2 of vaccine trials on humans to hasten the process.

The head of the Chinese Center for Disease Control and Prevention, Gao Fu, had also been injected with a potential vaccine on July 28, 2020. “I’m going to reveal something undercover: I am injected with one of the vaccines'' Gao Fu said in a webinar hosted by Alibaba Health, an arm of the Chinese e-commerce giant, and Cell Press, an American publisher of scientific journals. However, he did not reveal any more details about how and when exactly he administered himself with the vaccine and ‘hopes’ that the vaccine works.

Vladimir Putin, President of Russia | Source: Wikimedia

Elsewhere in Russia, on August 11, 2020, President Vladimir Putin proudly announced that Russia was the first country to grant regulatory approval to their vaccine after carrying out human trials for less than 2 months by the Gamalei Institute in Moscow. Regulatory approval permits vaccination of the masses. Although it has not undergone phase 3 of trials, Russia expects to initiate mass production of the vaccine by the end of this year. Kirill Dmitriev, head of Russia's sovereign wealth fund states that the vaccine will be called ‘Sputnik V’, named after Sputnik 1, the first satellite launched by Soveit Union which was a euphoric moment for Russia. More recently, China and Russia have joined hands in proceeding with the clinical trials of their vaccines.

These two instances seem to bring a new hope for the future, yet raise alarms and invite scepticism from the experts in the field of public health. One major concern is that without prolonged trials, vaccines should not be authorized for public use. Anthony Fauci, an infectious disease expert based in the US said “I do hope the Chinese and the Russians are actually testing the vaccines before they are administering the vaccine to anyone. Because claims of having a vaccine ready to distribute before you do testing is problematic at the very least”. Hence, some people are still in doubt regarding the safety of the product. Putin, however, rubbished such concerns and said "I know that it works quite effectively, forms strong immunity, and I repeat, it has passed all the needed checks".

An Indian biotechnological company, Bharat Biotech developed ‘Covaxin’ in collaboration with Indian Council for Medical Research (ICMR), using the mechanism of inactivated vaccine. It was successful in getting approval for human trials which were scheduled to begin in July, 2020. Initial reports stated that it would be ready for mass use by August 15, 2020, which also marked the 73rd Independence Day of India. However, Bharat biotech was clear in letting the public know that phase 1 of the trials are still on-going. ICMR cleared the confusion by stating that it would prepare the results of the phase 1 trials by August 15, 2020, not the actual vaccine for use. Phase 2 of the trials are awaited in September, 2020.

So far, the results of phase 1 trials have been positive as no serious side-effects are observed in the vaccine candidates. “The vaccine has been safe. No adverse effect has been reported. Even the point of injection pain, which is normal in vaccines, has been very mild” said Dr Kushwaha of Prakhar Hospital.

Meanwhile, the South Korean government stated on August 21, 2020, that it will secure adequate vaccine supply to its citizens by cooperating with international bodies and promoting local drug development. Three South Korean companies have started the process of making a vaccine and all are in the clinical trial phase. Bill Gates asserts that the South Korean pharmaceutical company, SK Bioscience, will have around 200 million vaccine doses ready by June 2021.

Japan is jointly collaborating with the UK, France and other European countries to establish a $20 billion fund to buy coronavirus vaccines, with Japan pledging a contribution of $800 million. It’s vaccine program aims to focus on giving primary attention to its medical workers and the elderly people of the country when the first doses of the vaccine are made. The state-funded vaccination program is believed to be officially adopted by Japan in September this year with negotiations with the UK and US based drug makers already in place.

With the race to bring COVID-19 vaccine seemingly coming to a close and it will hopefully be ready by the end of 2020 or early 2021. Till then, the entire world is watching this race with bated breath.

Read More